Liquidia Gestion

Gestion contrôle des critères 3/4

Le PDG Liquidia est Roger Jeffs, nommé en Jan2022, a un mandat de 2.83 ans. La rémunération annuelle totale est $ 4.89M, composée du salaire de 14.1% et des bonus 85.9%, y compris les actions et options de la société. détient directement 2.38% des actions de la société, d'une valeur de € 22.17M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 5.1 ans.

Informations clés

Roger Jeffs

Directeur général

US$4.9m

Rémunération totale

Pourcentage du salaire du PDG	14.1%
Durée du mandat du directeur général	2.8yrs
Propriété du PDG	2.4%
Durée moyenne d'occupation des postes de direction	3.3yrs
Durée moyenne du mandat des membres du conseil d'administration	5.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Roger Jeffs a-t-elle évolué par rapport aux bénéfices de Liquidia?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$119m
Jun 30 2024	n/a	n/a	-US$112m
Mar 31 2024	n/a	n/a	-US$108m
Dec 31 2023	US$5m	US$689k	-US$79m
Sep 30 2023	n/a	n/a	-US$58m
Jun 30 2023	n/a	n/a	-US$51m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$11m	US$325k	-US$41m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$41m
Dec 31 2021	US$93k	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$39m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$89k	n/a	-US$60m

Rémunération vs marché: La rémunération totale de Roger ($USD 4.89M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.48M ).

Rémunération et revenus: La rémunération de Roger a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Roger Jeffs (62 yo)

2.8yrs

Titularisation

US$4,889,498

Compensation

Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Roger Jeffs	CEO & Director	2.8yrs	US$4.89m	2.38% € 22.2m
Michael Kaseta	COO & CFO	4yrs	US$2.43m	0.12% € 1.1m
Russell Schundler	General Counsel & Corporate Secretary	3.7yrs	US$2.06m	0.39% € 3.6m
William Kenan	Co-Founder	20.8yrs	pas de données	pas de données
Ginger Denison	Co-Founder	20.8yrs	pas de données	pas de données
Sarah Krepp	Vice President of People & Culture	1.4yrs	pas de données	pas de données
Jason Adair	Chief Business Officer	1.3yrs	pas de données	0.072% € 674.3k
Scott Moomaw	Chief Commercial Officer	4yrs	pas de données	0.066% € 617.8k
Rajeev Saggar	Chief Medical Officer	2.3yrs	pas de données	0.099% € 922.4k
Michael Hunter	Senior Vice President of Manufacturing Operations	less than a year	pas de données	pas de données

3.3yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de LT4 est considérée comme expérimentée (ancienneté moyenne 3.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Roger Jeffs	CEO & Director	4yrs	US$4.89m	2.38% € 22.2m
Arthur Kirsch	Independent Director	8.2yrs	US$186.91k	0.038% € 351.8k
Joanna Horobin	Independent Director	5.2yrs	US$176.91k	0% € 0
Burton Goldstein	Board Observer	no data	pas de données	pas de données
Michael Raab	Board Observer	no data	pas de données	pas de données
Martin Lagod	Board Observer	no data	pas de données	pas de données
Stephen Bloch	Independent Chairman	15.3yrs	US$211.91k	0% € 0
Paul Manning	Independent Director	4.8yrs	US$170.66k	7.26% € 67.6m
David Johnson	Independent Director	3.6yrs	US$174.41k	0% € 0
Damian deGoa	Director	3.9yrs	US$166.91k	0.056% € 524.6k
Ramandeep Singh	Independent Director	6.8yrs	US$178.16k	0% € 0
Katherine Rielly-Gauvin	Independent Director	5.1yrs	US$175.66k	0% € 0

5.1yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de LT4 sont considérés comme expérimentés (ancienneté moyenne 5.1 ans).

Liquidia Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

Insufficient new directors

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

Insufficient new directors

Liquidia Corporation Announces Updates to Operations Leadership

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 3Q 2023)

New minor risk - Profitability

Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024

Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024

Insufficient new directors

Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million.

Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD

New minor risk - Profitability

No longer forecast to breakeven

Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.36 loss in 2Q 2023)

Insufficient new directors

Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024

District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch

No longer forecast to breakeven

Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024

Liquidia Corporation, Annual General Meeting, Jun 20, 2024

Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder

Insufficient new directors

Full year 2023 earnings released: US$1.21 loss per share (vs US$0.67 loss in FY 2022)

Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder

Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder

Liquidia Corporation Announces Updates to Operations Leadership

Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims

Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD

Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP

Insufficient new directors

Forecast to breakeven in 2026

Independent Director recently bought €1.8m worth of stock

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million.

Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.

Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023

FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label

United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office

New minor risk - Profitability

Second quarter 2023 earnings released: US$0.36 loss per share (vs US$0.15 loss in 2Q 2022)

Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023

Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder

Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 3Q 2021)

Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022

High number of new directors

Liquidia Corporation Provides Update on Hatch-Waxman Litigation

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.13 loss in 2Q 2021)

Liquidia Corporation to Report Q2, 2022 Results on Aug 11, 2022

Liquidia Corporation Announces the Publication of Long-Term Clinical Data from Completed INSPIRE Study in the Journal Pulmonary Circulation

Liquidia Receives Favorable Ruling in Inter Partes Review Against United Therapeutics Patent

High number of new directors

Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer

Chief Operations Officer recently bought €93k worth of stock

High number of new directors

Liquidia Corporation to Report Q1, 2022 Results on May 12, 2022

Liquidia Corporation, Annual General Meeting, Jun 16, 2022

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $50.000002 million.

Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $50.000002 million.

High number of new directors

High number of new directors

Forecast to breakeven in 2024

High number of new directors

Liquidia Corporation Announces Stipulation of Partial Judgment In Favor of Liquidia Filed in Hatch-Waxman Litigation

General Counsel & Corporate Secretary recently bought €431k worth of stock

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction